Timothy Brewerton
Affiliate Professor of Psychiatry and Behavioral Sciences at the Medical University of South Carolina
Data updated
Research Footprint
Timothy Brewerton appears in 5 tracked papers (2012–2025), most studied alongside MDMA and Psilocybin, across PTSD, Eating Disorders and Substance Use Disorders (SUD).
Most-cited paper: Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study (372 citations).
Frequent co-authors: Michael Mithoefer, Rick Doblin and Berra Yazar-Klosinski.
Background & Research
Timothy D. Brewerton, MD, is a psychiatrist with a long career focused on eating disorders, trauma, PTSD, and comorbid psychiatric conditions. He is affiliated with the Medical University of South Carolina as an Affiliate Professor of Psychiatry and Behavioral Sciences and has published on the use of MDMA- and psilocybin-assisted therapy in psychiatric and eating-disorder contexts. His work also includes broader research on trauma-informed care, serotonin dysregulation, and the medical/psychiatric consequences of adverse childhood experiences.
Key Impact
He is a leading eating-disorders psychiatrist whose work has helped connect trauma, PTSD, and psychedelic-assisted therapy research, including MDMA and psilocybin studies.
Collaboration Network
11 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Timothy Brewerton is associated with.
Medical University of South Carolina
The Medical University of South Carolina (MUSC) is a public academic health sciences center in Charleston, South Carolina, founded in 1824. It comprises multiple colleges (Medicine, Dental Medicine, Health Professions, Nursing, Pharmacy, and Graduate Studies) and provides education, biomedical research, and clinical care across the state.
View stakeholder →MAPS
nonprofitMAPS, the Multidisciplinary Association for Psychedelic Studies, is a U.S.-based 501(c)(3) nonprofit research and educational organization founded in 1986. It works nationally and with a broader global audience to develop medical, legal, and cultural contexts for the careful use of psychedelics and marijuana. Its core activities include research, education, advocacy, and convening the field through large public events. In psychedelic medicine and policy, MAPS positions itself as an advocate for legal access, drug policy reform, harm reduction, and health equity. Its Policy & Advocacy work includes legislative advocacy, community organizing, and impact litigation, and it has also launched work on access for system-impacted people and broader health equity in the legal psychedelic ecosystem. Current documented initiatives include the Psychedelic Science conference series, the Health Equity Program, The Zendo Project, and Ask MAPS, which handles public inquiries about therapy, research, and policy reform.
View stakeholder →